Hematology-OncologyCAR T-cell therapyoverall survival
CAR T-Cell Therapy Revolutionizes Outcomes in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: Insights from Pooled REPRIME-FIL and CART-SIE Analyses
By MedXY|Oct 1, 2026
A pooled analysis of REPRIME-FIL and CART-SIE studies shows CAR T-cell therapy significantly improves overall survival in relapsed/refractory primary mediastinal B-cell lymphoma compared to traditional salvage treatments including ASCT.